Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Businessweek Archives

Ethics


Washington Outlook: CAPITAL WRAPUP

ETHICS

Charges of fraud in government-sponsored research have gotten the headlines, but it's new federal conflict-of-interest rules that are riling the scientific community. Regulations drafted by the National Institutes of Health would require universities to adopt ethics standards that would, among other things, bar scientists from holding certain kinds of stock in companies that hire them to run clinical trials of drugs. The difficulty is that cash-poor small companies often pay scientists in stock. Researchers fear the new rules would stifle drug development. But congressional critics think the NIH hasn't gone far enough. Representative Ted Weiss (D-N. Y.) is pushing for legislation imposing even more stringent conflict-of-interest requirements.EDITED BY STEPHEN H. WILDSTROM


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus